Epivax Oncology

EpiVax Oncology is a small, privately held biotechnology company based in New York, New York. With a team of four employees, they generate approximately $2.5 million in annual revenue. EpiVax Oncology is dedicated to developing innovative cancer treatments tailored to individual patients. Their focus lies in precision cancer immunotherapies using a novel approach called mutanome-directed neo-epitopes. This involves identifying unique mutations within a patient's tumor, which are then used to design personalized therapeutic vaccines. These vaccines aim to trigger a potent and specific immune response against cancerous cells, leading to improved clinical outcomes. EpiVax Oncology distinguishes itself through its proprietary in silico predictive algorithms, which play a crucial role in identifying and selecting the most effective neo-epitopes for each patient's treatment. The company leverages its extensive expertise in computational immunology, genomics, and vaccine design, accumulated over two decades. EpiVax Oncology can be reached through their website at epivaxonco.com.